NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
Clinical Trials
9 trialsNCT02745353 2019-12-09
Naloxegol in Cancer Opioid-Induced Constipation
University of California, San Diego
Phase 2 Terminated
NCT01189409 2019-08-28
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
British Columbia Cancer Agency
Phase 4 Terminated
NCT02839889 2019-03-05
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
Hospice of Henderson County, Inc.
Phase 4 Terminated
NCT01696643 2018-11-15
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901302 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901341 2018-11-15
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01004393 2016-02-02
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
University of Vermont
Phase 2 Completed
NCT00984334 2013-12-27
Naloxone SR Capsules in Patients With Opioid Induced Constipation
S.L.A. Pharma AG
Phase 2 Completed